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Background: Plants are the valuable source of natural products with important medicinal properties. Most of the
approved anti cancer drugs have a natural product origin or are natural products. Retinoblastoma is the most
common ocular cancer of children. Although chemotherapy is the preferred mode of therapy, a successful
treatment for retinoblastoma requires enucleation. Chebulagic acid (CA) from Terminalia chebula was shown to
have anti-proliferative properties in the studies on cancerous cell lines. Due to anti cancer properties of CA and due
to limitation in treatment options for retinoblastoma, the present study is undertaken to understand the role of CA
on the proliferation of retinoblastoma cells.
Methods: Anti proliferative potential of CA was determined by MTT assay. The expression levels of various cell
death mediators in retinoblastoma cells with CA treatment were assessed by Western blotting. Flowcytometer
analysis was used to estimate the mitochondrial membrane potential (MMP) and to determine the percentage of
cells undergoing apoptosis.
Results: The present study showed CA inhibited the proliferation of retinoblastoma cells in a dose dependent
manner. CA modulated MMP, induced release of Cytochrome c, activated caspase 3 and shifted the ratio of BAX
and Bcl2 towards cell death. G1 arrest, noticed in CA treated cells, is mediated by the increase in the expression of
CDK inhibitor p27. CA treatment also decreased the levels of NFκB in the nucleus. This decrease is mediated by
suppression in degradation of IκBα.
Conclusion: CA has shown significant anti proliferative potential on retinoblastoma cells. Our findings clearly
demonstrate that CA induces G1 arrest, inhibits NFκB and induces apoptosis of retinoblastoma cells.
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Natural products from plants are considered as a valuable
source of active drug substances and a majority of modern
drugs. Drugs derived from plants or microbes which are
in preclinical development or in clinical phase are dis-
cussed in detail elsewhere [1]. In addition to the stand
alone natural products, there is also a growing interest in
the combination of natural products, being effective or ef-
ficacious in a particular pathological condition and such
combinations were also approved for human use by* Correspondence: roykarnati@gmail.com
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reproduction in any medium, provided the orregulatory authorities [2]. Plant derived natural products
were also explored from treatment of cancers. Paclitaxel,
camptothecin, etoposide, vinblastine and vincristine are all
plant derived natural products approved for clinical use in
many cancers. Epidemiological studies also show the be-
neficial effects of some fruit and vegetable diet against
cancers [3,4]. Bioflavonoids, isoflavonoids, β carotenes,
phenols, polyphenols, catechins, alkoloids, lectins were
shown to have anti proliferative potential in several
cancers [5-9].
Natural products alone or in combination with standard
drugs were shown to be effective against retinoblastoma
[10-12]. Retinoblastoma is the most common ocular
tumor of children. In the majority of cases the survivalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ment of retinoblastoma is achieved by enucleation [13]. At
present treatment options include radiotherapy, chemo-
therapy, thermotherapy and brachytherapy [13,14]. Many
complications arise due to the conventional therapies such
as impaired vision due to cataracts and retinopathy [13],
gastrointestinal disorders, neurotoxicity [15-19]. Carbo-
platin, etoposide and vincristine are synergistically used in
chemotherapy of retinoblastoma [13]. Secondary cancers
are induced due to the conventional therapies in children
of lower age [14,20-22].
Inhibition of the molecular pathways having role in cell
proliferation is a widely used strategy in anti cancer drug
development. NFκB is an anti apoptotic transcription factor
which plays an important role in the cell survival signaling.
Interaction with IκB makes NFκB to reside in the cyto-
plasm as a dimer. Cell proliferation inducers mediate rapid
degradation of IκB, promotes translocation of NFκB to the
nucleus and induces the expression of several anti apoptotic
protein including BCL2 family members [23,24]. p27 regu-
lates cell cycle transition and increase in the expression of
p27 arrests the cells in G1 phase and restricts entry into S
phase. p27 is phosphorylated by CDK 2–cyclin E and this
phosphorylation of p27 results in its degradation through
ubiquitin mediated proteosomal degradation [25]. NFκB
activity is constitutively required for the survival and
proliferation of retinoblastoma cells [26].
Natural products are being explored for effective therapies
and to reduce complications due to conventional chemo-
therapy in retinoblastoma. Few studies were successful in
showing anti proliferative potential. Resveratrol inhibits pro-
liferation of retinoblastoma cells by activating mitochondrial
mediated apoptosis [27]. Abelmoschus moschatus extracts
showed potent anti oxidant and anti proliferative activity in
retinoblastoma [10]. Plant derived natural products like
peruvoside, ouabain, neriifolin, digoxin, and digoxigenin in-
duced greater than 75% inhibition in at least one retinoblast-
oma cell line [11]. Paclitaxel (PTX), a diterpene taxane,
induced apoptosis in retinoblastoma cells along with beta
lactophone [12].
In our previous studies we have shown CA from
Terminalia chebula as a potent suppressor of lipopolysac-
charide induced inflammation in mouse macrophages [28].
CA further showed broad spectrum anticancer effects on
HCT-15 (colon), COLO-205 (colon) cell lines [29]. Termi-
nalia chebula, amember of the Combretaceae family, native
of India, is being used in alternative medicine. The dried
fruits are being used for treatment for conditions of asthma,
cough, bloody stools, heart and bladder disease [30]. The
fruits are rich in high molecular weight tannins [31,32].
Benzopyran tannins are one of the major components in the
fruits of Terminalia chebula. CA, a benzopyran tannin, was
reported as a COX-2/5-LOX dual inhibitor [29]. CA has
been shown to inhibit ROS generation [33] and anti-hyperglycemic activity [34]. CA was also reported to allevi-
ate arthritis in mice models [35] and inhibited LPS-induced
Nitric oxide [36]. CA and punicalagin were shown to inhibit
HSV-1 entry in A549 human lung cells by preventing
binding, penetration, and cell-to-cell spread [37]. In addition
to these reported studies, CA is the main constituent of
Triphala, a well known ayurvedic medicine used to treat
allergies and common health disorders in India.
Due to several important medicinal properties of CA and
limitation of the current conventional therapies in retino-
blastoma, the present study is undertaken to understand
the effect of CA on the proliferation of retinoblastoma cells
and elucidate the molecular mechanisms involved.
Methods
Chemicals
DMEM, FBS, Rhodamine 123, Propidium iodide were
purchased from Gibco BRL. MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide], protease
inhibitor cocktail and TMB/H2O2, DAPI, Ac-DEVD-pNA,
z-VAD-FMK were from Sigma-Aldrich. Nitrocellulose
and PVDF membranes were from Millipore. Monoclonal
antibodies of Cytochrome c, BAX, Bcl2, p27, NFκB-p65,
IκBα and β-actin were from Cell Signaling technologies
and Millipore. All the other chemicals and reagents were
purchased from local companies and are of molecular
biology grade. Chebulagic acid was isolated from fruits of
Terminalia chebula as described previously [29]. Fruit
material of Terminalia chebula (Combretaceae) authenti-
cated by Prof. K. Seshagirirao, and the dried drupes were
deposited at University of Hyderabad Herbarium (UH)
[University of Hyderabad, Hyderabad 500046, India]
repository with Specimen No. 1006-KRRMR.
Cell culture
Retinoblastoma cells Y79 were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% (v/v)
heat-inactivated FBS, 100 IU/ml penicillin, 100 mg/ml
streptomycin and 2 mM L-glutamine. Human corneal epi-
thelial cells were grown in MEM alpha medium supple-
mented with EGF (0.1 mg/l) and insulin (5 mg/l). Both
cultures were maintained in a humidified atmosphere with
5% CO2 at 37°C. The cultured cells were passed twice each
week, seeding at a density of approx. 2 × 103 cells/ml. Cell
viability was determined by the Trypan Blue dye exclusion
method before seeding for each experiment.
Cell proliferation assay
Cell proliferation of Y79 cells with CA treatment was deter-
mined by the MTT assay. Y79 cells were seeded in 96-well
plate in the presence or absence of CA (0.001, 0.01, 0.1, 0.5,
1, 5, 10, 25, 50 and 100 μM) for 24 h at a density of 5 × 103
cells/well in a volume of 100 μl medium. After incubation,
20 μl of MTT at a concentration of 5 mg/ml was added.
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added to each well. Plates were agitated for 1 min and
absorbance was read at 570 nm on a multi-well plate
reader. The percentage of the inhibition of prolifera-
tion was calculated as a fraction of control (without CA
treatment). To assess the effect of CA on non cancerous
cells, Human corneal epithelial cells were used under
similar treatment conditions.
Cell morphology analysis
Y79 cells (1 × 105) were incubated with CA (50 μM) for
24 h. Cells were observed and photographed for morpho-
logical changes under a phase contrast inverted microscope.
Nuclear morphology and DNA fragmentation analysis
Y 79 cells at a density of 1 × 105 were grown overnight in a
cell culture dish. The cells were then incubated with CA
(50 μM) for 24 h. After incubation, cells were washed with
1 × PBS and mounted on to the slide with the mounting
medium containing DAPI. The slides were then observed
for changes in nuclear morphology in an Olympus inverted
fluorescence microscope. For DNA fragmentation assay, Y
79 cells (5 × 106 cells) were incubated at 37°C with CA
(50 μM) for 24 h. After treatment, cells were washed in cold
PBS and lysed in a buffer containing 50 mM Tris (pH 8.0),
1 mM EDTA and 0.2% Triton X-100 for 20 min at 4°C.
After centrifugation at 14 000 g for 15 min, the supernatant
was treated with proteinase K (0.5 mg/ml) and 1% SDS for
1 h at 50°C. DNA was extracted twice with phenol and
precipitated with 140 mM NaCl and 2 volumes of ethanol
at −20°C overnight. DNA precipitates were washed twice in
70% (v/v) ethanol, dissolved in TE buffer, and treated for
1 h at 37°C with RNase A. Finally, DNA preparations
were electrophoresed in 1% agarose gel, stained with
ethidium bromide and observed under UV light.
Cell cycle analysis by flow cytometer
Y 79 cells were seeded at a density of 4 × 105 in 6-well cul-
ture plates, grown overnight in medium containing 10%
FBS with or without CA (50 μM) for 24 h. After treatment
cells were washed with 1 × PBS. For the cell cycle analysis,
cells were fixed in 70% ice cold ethanol, washed with 1 ×
PBS, incubated with RNase A (0.1 mg/ml) and stained with
propidium iodide (PI) (50 mg/ml). Flow cytometric analyses
were performed by using a BD Calibur machine (San Jose,
CA, U.S.A.) as previously described [38]. The fluorescence
intensity of PI was detected with FL2-H detector. X axis on
the histogram represents PI fluorescence intensity and Y
axis represents number of cells at particular fluorescence
intensity.
Measurement of mitochondrial membrane potential (MMP)
Y79 cells, at a density of 4 × 105 were seeded in 6-well
culture plates and cultured with or without CA (50 μM) for24 h. After the treatment, cells were incubated with
Rhodamine 123 (10 μg/ml) for 30 min. After the incuba-
tion, cells were washed with 1 × PBS. MMP was assessed
on a flow cytometer. Data were collected using the data
acquisition program CELL Questpro and fluorescence
was measured using an FL-1H detector as previously de-
scribed [38]. Ten thousand cells were analysed per sample.
The fluorescence intensity of Rhodamine was detected
with FL1-H detector. X axis on the dot plot represents
Rhodamine fluorescence intensity and Y axis represents
SSC-H (side scatter) indicating the granular content of the
cells.Assessment of caspase 3 activity
Caspase-3 activity in the lysates of Y79 cells treated with
CA (50 μM) and untreated cells. 100 μg of total protein
was incubated with Caspase 3 specific peptide (Ac-DEVD-
pNA) at a final concentration of 200 μM at 37°C for 2 h in
dark. The absorbance was read at 400 nm. Cells were pre-
treated with a pan-caspase inhibitor (z-VAD-FMK) for 3 h
at a concentration 20 μM before the cells were treated with
CA (50 μM) and cell proliferation was estimated by MTT
assay.Western blotting
Y79 cells were seeded at a density of 5 × 106 in 100 mm
culture dishes. They were incubated with CA (50 μM) for
0, 3, 6, 12, 24 and 48 h. After incubation with CA, cells
were washed with 1 × PBS and suspended in cell lysis
buffer with 1 mM PMSF, 10 μg/ml leupeptin, 20 μg/ml
aprotinin and phosphatase inhibitor cocktail. After 30 min
of intermittent vortexing at 4°C, the cell lysate was centri-
fuged (10 000 g) for 30 min, and the supernatant were used
as the whole cell extract. Nuclear and cytoplasmic extracts
were also prepared as described previously [39]. The pro-
tein content was estimated by the Bradford method [40].
100 μg of either total or nuclear or cytosolic protein from
each treatment were resolved on 7–12% SDS PAGE gels
along with protein molecular weight markers and then
transferred on to nitrocellulose or PVDF membranes.
Membranes were stained with 0.5% ponceau stain to check
the transfer. The membranes were blocked with 5% (w/v)
BSA and then incubated with the primary antibodies [BAX
(1:250 dilution), Bcl-2,(1:500 dilution), Cytochrome c (1:250
dilution), p27 (1:500 dilution), NFκB-p65 (1:500 dilution),
IκBα (1:500 dilution), β-actin (1:1000 dilution)] in 10 ml of
antibody-dilution buffer (1 × Tris-buffered saline and 0.05%
Tween 20 with 1% BSA) with gentle shaking at 4°C for
8–12 h and then incubated with peroxidase or alkaline
phosphatase conjugated secondary antibodies. The signals
were detected by using peroxidase or alkaline phosphatase
substrates. The band intensity was quantified by Image J
software.
(A)
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Results are reported as the Mean± S. E. M. for three inde-
pendent experiments. Statistical analysis was carried out by
Student’s t test. A p-value of less than 0.01 for each concen-
tration versus control was considered to indicate significance.(B)Results
Y79 cell proliferation was inhibited by CA
Y79 cells were treated with CA (0.001, 0.01, 0.1, 0.5, 1, 5, 10,
25, 50 and 100 μM) for 24 h and cell proliferation was deter-
mined by the MTT assay. CA treatment decreased the pro-
liferation of Y79 cells in a dose dependent manner. At a
concentration of 50 μM of CA, a 50% decrease in Y79 cell
proliferation was observed (Figure 1) in 24 h. Normal human
corneal epithelial (HCE) cells were treated with CA at same
concentration as that of Y79 cell treatment. CA at 50 μM
concentration could inhibit only 20% of HCE cell prolifera-
tion compared to 50% in Y79 cells. Further experiments
were carried out with 50 μM CA as 50% inhibition of Y79
cell proliferation was observed at this concentration.Figure 2 Effect of CA on morphology of Y79 cells. (A) Control cells
(B) CA (50 μM; 24 h) treated cells.Y79 cell morphology altered with CA treatment
Treatment of cells with cell death inducing agents alters
the morphology of cells. Disruption of membrane and
formation of membrane blebs are commonly observed.
Untreated Y79 cells grow in grape like clusters (Figure 2A),
but with CA treatment, morphology and growth pattern
of the cells changed considerably. Y79 cells with CA treat-
ment showed distorted morphology, membrane blebs and
less clusters (Figure 2B).Concentration (µM)






















Figure 1 Effect of CA on the proliferation of retinoblastoma and
normal human corneal epithelial cells. Y79 and HCE cells were
treated with 0.001, 0.01, 0.1, 0.5, 1, 5, 10, 25, 50 and 100 μM
concentration of CA for 24 h. The percentage of viable cells with
treatment was calculated in comparison with untreated control cells.
The number of cells in the control was taken as 100%. Data was
represented as mean ± S.E.M of three independent experiments.
*P < 0.01 vs untreated control was considered to indicate significance.CA induced nuclear and DNA fragmentation in Y 79 cells
Nuclear fragmentation, which is observed during apop-
tosis, is observed using a nuclear stain DAPI. In CA
(50 μM) treated cells, fragmented nuclei were observed
(Figure 3B) and the nuclei were intact in untreated control
cells (Figure 3A). Cells treated with CA (50 μM) showed
fragmentation of DNA, similar to the cells undergoing
apoptosis (Figure 3C).
Mitochondrial membrane depolarization was observed
with CA treatment
Mitochondria play a key role in apoptosis. A change in the
membrane potential of mitochondria is a critical step in
the induction of apoptosis. MMP was assessed using
Rhodamine 123 by flow cytometric analysis. In Figure 4, X
represents FL1-H, detector for Rhodamine in the flow
cytometer. Y represents SSC-H, detector for granularity of
cells. The cells on the higher scale of FL1-H represent
cells with higher membrane potential. In control un-
treated cells majority of cells are on higher FL1H scale
(Figure 4A). Treatment with CA 50 μM, induced a shift in
the significant cell population towards the lower scale of
(B)(A)
(C) 1               2            3 
Figure 3 Effect of CA on nucleus morphology and DNA fragmentation of Y79 cells. (A) DAPI stained nucleus of control cells (B) DAPI
stained nucleus of CA (50 μM; 24 h) treated cells (C) Lane 1, 100 bp DNA ladder; lane 2, DNA of control cells; lane 3, DNA of CA (50 μM; 24 h)
treated cells.
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(Figure 4B) and the treatment also resulted in decrease in
cell granularity i.e. SSC-H, due to cell death.
Ratio of Bcl2 and BAX shifted towards apoptosis with CA
treatment
Ratio of Bcl2 and BAX proteins decides the fate of the cells
towards cell survival or cell death. Due to the decrease in
the expression of anti-apoptotic protein Bcl2 and increase
of expression of pro-apoptotic protein BAX, the cells die of
apoptosis. Y79 cells treated with CA (50 μM) showed a
time dependent increase in expression of BAX (Figure 5A)
and decrease in expression of Bcl2 until 24 h and total
absence at 48 and 72 h (Figure 5B).
CA induced the release of Cytochrome c
Release of Cytochrome c into the cytosol as a result of
mitochondrial depolarization initiates the intrinsic pathway
of apoptosis. Western blot analysis with the cytoplasmic
extracts devoid of mitochondria with anti-Cytochrome c
antibodies was performed. A time dependent increase inCytochrome c release in Y79 cells treated with CA (50 μM)
was observed (Figure 5C). Untreated cells showed no
release of Cytochrome c.
CA induced apoptosis is Caspase 3 dependent
Caspase-3 activity increased in the lysates of Y79 cells
treated with CA (50 μM) compared to that in untreated
cells (Figure 6A). To show that CA induced cell death is
caspase 3 dependent, MTT assay was done with CA, in the
presence and absence of a pan-caspase inhibitor
(z-VAD-FMK). Caspase inhibitor could inhibit the CA
induced cell death in Y 79 cells (Figure 6B).
CA treatment increased the number of Y79 cells in
hypodiploid and G1 phases
Number of hypodiploid cells increases with apoptosis.
Induction of apoptosis with CA treatment was quantified
by flowcytometric analysis. X represents FL2-H, detector
for Propidium Iodide in the flow cytometer. Y represents
counts, representing number of cells at particular FL2-H.
Propidium Iodide is a DNA binding dye and proportion of
(A) 
(B) 
Figure 4 Effect of CA on mitochondrial membrane potential of
Y79 cells. Cells were treated with CA (50 μM) for 24 h and incubated
with Rhodamine 123 (10 μg/ml) for 30 min fluorescence was quantified
by FACS. (A) Control cells (B) CA (50 μM; 24 h) treated cells.





























Figure 5 Effect of CA on expression of cell death mediator
proteins. Y79 cells treated with CA (50 μM) for different time
periods (0, 3, 6, 12, 24 and 48 h). Equal amounts of total protein
(BAX, Bcl2 and β-actin) and cytosolic protein (Cytochrome c)
(100 μg) was analysed by SDS- PAGE 7–12%, and after electrophor-
esis, proteins on the gel were transferred on to nitrocellulose mem-
brane and probed with protein-specific antibody. Lane 1, 0 h; lane 2,
3 h; lane 3, 6 h; lane 4, 12 h; lane 5, 24 h; lane 6, 48 h. (A) BAX; (B)
Bcl2; (C) Cytochrome c (D) β-actin. Bar graphs represents mean rela-
tive expression of protein normalised against β-actin.
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cell. In a dividing cells, the quantity of DNA in different
phases of cell cycle varies as G1 < S < G2/M. The marker
(M1) represents the cells before G1 peak, indicating the
cells which are having less DNA (hypodiploid) than G1
phase cells. These hypodiploid cells are the cells under-
going cell death. In the Figure 6, we can clearly observe,
the increase in number of cells before G1 peak with CA
(50 μM) treatment compared to untreated cells. Untreated
control cells showed prominent G1 (59%), S (12%) and
G2/M (27%) phases with minimal 1% in sub G1 hypodip-
loid stage (Figure 7A). Treatment with CA increased the%
of cells in sub G1 phase and G1 phase to 12% and 76%
respectively (Figure 7B). These results indicate that CA
treatment arrested the cells in G1 stage of cell cycle and
also induced apoptosis.
CA induces G1 arrest and inhibits NFκB
p27 and NFκB are important regulators of cell cycle pro-
gression and proliferation. As increase in% of cells in G1
phase was observed, the expression levels of p27 were
estimated. With CA (50 μM) treatment, a time dependent
increase in expression of p27 was observed (Figure 8C),
indicating CA mediated G1 arrest is through p27. Levels
of NFκB are altered with proliferative status of cells.
NFκB-p65 levels decreased in the nuclear extracts of Y79cells with CA treatment (Figure 8A), where as IκBα levels
increased (Figure 8B). These results indicate CA sup-
pressed the degradation of IκBα, there by inhibiting the
translocation of NFκB to nucleus.
Discussion
Plants are the source of many clinically used potent
anti-cancer molecules [1]. The enormous diversity of the
plants was not explored and screened extensively for
potential therapeutic molecules [41,42]. Exploration of
plants for natural products even makes it more relevant
these days, with the advances in the methods and tech-















Con CA (50 uM)




















Figure 6 Effect of CA on activation of caspase 3. (A) Cells were
treated with CA (50 μM) for 24 h, and lysates were analysed for caspase
3 activation. (B) Proliferation of CA (50 μM) treated Y79 cells for 24 h in
the presence and absence of pan caspase inhibitor, z-VAD-FMK.
(B)
(A)
Figure 7 Effect of CA on the cell cycle of Y79 cells. Cells were
treated with CA (50 μM) for 24 h, fixed, and stained with propidium
iodide, and the DNA content was quantified by FACS. The number
of cells in hypodiploid (subG0/G1) and G1 phase is expressed as a
percentage of the total number of cells. (A) Control cells (B) CA
(50 μM; 24 h) treated cells.
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anti-cancer properties of natural products isolated from
various sources [44-46]. Our group has shown CA iso-
lated from Terminalia chebula inhibits LPS induced in-
flammation [28], inhibits proliferation of colon cancer
cells [29]. In addition to these properties several groups
have shown beneficial properties of CA [33-37]. Current
therapies to retinoblastoma are limited necessitating the
patient to undergo enucleation. Due to several medicinal
properties of CA, the present study is planned to under-
stand the effect of CA on retinoblastoma cell line, Y79,
and to understand the molecular mechanisms involved.
Y79 cells when treated with CA showed a dose dependent
inhibition of cell proliferation. We observed 50% inhibition
of Y79 cell proliferation at 50 μM concentration of CA. At
the same concentration CA could only inhibit 20% prolife-
ration of normal HCE cells. This indicates CA is more
specific towards cancer cells. These differential effects of CA
on cell proliferation between cancer and normal cells might
be due to differences in constituent expression of the cellu-
lar protein signatures like constitutive NFκB expression [26].Retinoblastoma cells grow in clusters, but with the CA
treatment, the morphology and growth pattern of the cells
changed considerably. Y79 cells with CA treatment showed
distorted morphology, membrane blebs and less cell clus-
ters. Nuclear and DNA fragmentation, a hallmark property
of cells undergoing apoptosis, was observed in Y79 cells
with CA treatment.
MMP is critical for proper cellular functions. Depolarized
mitochondria lead to leakage of the membrane leading to
release of Cytochrome c and formation of apoptosome
complex [47]. Rhodamine 123 was used to assess the MMP
in CA treated Y79 cells by flowcytometric analysis. Treat-
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Figure 8 Effect of CA on the expression of NFκB-p65, IκBα and p27 proteins. Y79 cells treated with CA (50 μM) for different time periods
(0, 3, 6, 12, 24 and 48 h). Equal amounts of total protein (IκBα, p27and β-actin) and nuclear protein (NFκB-p65) (100 μg) was analysed by
SDS- PAGE 7–12%, and after electrophoresis, proteins on the gel were transferred on to nitrocellulose membrane and probed with NFκB-p65,
IκBα, p27and β-actin specific antibodies. Lane 1, 0 h; lane 2, 3 h; lane 3, 6 h; lane 4, 12 h; lane 5, 24 h; lane 6, 48 h. Bar graphs represents mean
relative expression of protein normalised against β-actin. (A) NFκB-p65, (B) IκBα, (C) p27, (D) β-actin.
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scale on x axis of the dot plot. This disruption of MMP
might alter the membrane dynamics of mitochondria lead-
ing to the molecular events triggering cell death. Similar
disruption in membrane potential was observed with meth-
anolic extracts of Gracilaria tenuistipitata in oral cancer
cells [38,48].
Bcl2 family members regulate the mitochondrial path-
way of apoptosis. They are either pro apoptotic (Bak or
Bax) or anti apoptotic (Bcl2 or Bcl XL). These proteins
play role in permeabilization of the mitochondrial outer
membrane on receiving apoptotic signals. Permeabilization
leads to release of Cytochrome c, formation of apoptosome
complex, activation of caspases, thus triggering morpho-
logical changes like membrane blebbing and nuclearfragmentation. Expression ratio of pro apoptotic BAX and
anti apoptotic Bcl2 is the critical factor in driving cells to-
wards life or death. Cells undergoing apoptosis show an in-
crease in the expression of BAX and a decrease in the
expression of Bcl2. 7α-hydroxy-β-sitosterol, a natural phy-
tosterol oxide was shown to induce apoptosis by altering
Bcl2/BAX ratio [49]. In our study, Y79 cells treated with
CA shifted the ratio of Bcl2 and BAX towards cell death by
increasing expression of BAX and decreasing the expres-
sion of Bcl2, release of cytochrome c and activation of cas-
pase 3.
NFκB is a proliferating promoting protein and is
activated in majority of tumors. NFκB translocates to the
nucleus and activates transcription of several genes which
are involved in cell proliferation. Bcl2 expression is
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indicating anti apoptotic Bcl2 might be regulated by NFκB
[24]. The activation of NFκB is regulated by IκBα. We
estimated the expression levels of NFκB and IκBα using
western blotting. Treatment of retinoblastoma cells with
CA inhibited the translocation of NFκB to the nucleus.
CA suppressed the degradation of IκBα. This increase in
levels of IκBα might have effected the translocation of
NFκB to nucleus, effecting expression of several genes
involved in Y79 cell proliferation. Similar NFκB mediated
inhibition of cell proliferation was shown by natural
products and plant extracts [50,51].
Most of the anti cancer agents target the cell cycle of the
cancer cells and this property to alter the cell cycle is
considered one of the important property in the anti cancer
drug development [52]. Progression of cell cycle is regu-
lated by CDK inhibitor, p27. Increase in the expression of
p27 inhibits the cell cycle entry into S phase [25]. Cell cycle
analysis of the Y79 cells treated with CA showed an
increase apoptotic or hypodiploid cells. We could also
observe an increase in number of cells in G1 phase with
CA treatment. Western blot analysis of p27 also showed a
time dependent increase in expression, which indicates that
CA induces G1 arrest by the induction of p27 expression.
The present study thus demonstrates that CA induces
apoptosis in retinoblastoma cell line Y79 by altering expres-
sion of Bcl2 family members, activating caspase 3, disrupt-
ing MMP and interfering with the NFκB cell proliferation
pathway (Figure 9).
Conclusions
Our findings clearly demonstrate that CA induces G1 ar-
rest, inhibits NFκB and induces apoptosis of retinoblastoma
Y79 cells. CA induced the release of Cytochrome c byFigure 9 Proposed schematic model for chebulagic acid
mediated G1 arrest and apoptosis of Retinoblastoma cells Y79.modulating the MMP and altering BAX and Bcl2 ratio
towards apoptosis. CA induced apoptosis of Y79 cells is
caspase 3 dependent. G1 arrest in the Y79 cells with CA
treatment is mediated by the increase in the expression of
CDK inhibitor p27. CA inhibited the nuclear translocation
of NFκB by suppressing the degradation of IκBα. This study
highlights the potential of CA in inhibiting the proliferation
of retinoblastoma cells. Further studies are required to
assess the in vivo anti proliferative potential of CA. CA and
any other analogs derived from it may be explored and
validated further for its usefulness as anti cancer agents for
retinoblastoma and other cancers.
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